Publicly traded Mentor Capital, a San Diego-based firm that acquires and invests in “leading-edge” cancer companies, has agreed to pay $5 million for a 50 percent ownership stake in Houston-based Brighter Day Health, pending shareholder approval. Brighter Day provides face-to-face doctor interaction through secure computer video set-ups for health care delivery at nursing homes and other treatment facilities.
Mentor Capital, Inc. (OTC Markets: MNTR) announced that it has executed a long-term funding agreement to receive a current 50% ownership in Brighter Day Health, LLC, pending their expected shareholder approval. Brighter Day provides face-to-face doctor interaction through secure computer video set-ups for ultra-economic health care delivery at nursing homes and similar treatment facilities. Mentor Capital is to provide $5.0 Million in future growth funding for Brighter Day Health to continue its multi-state expansion plan.
“Reducing the cost and inconvenience of the routine or follow-up doctor visit for often challenged cancer or other patients is an obvious plus for all parties involved with a compromised patient”
“Reducing the cost and inconvenience of the routine or follow-up doctor visit for often challenged cancer or other patients is an obvious plus for all parties involved with a compromised patient,” says Mentor Capital CEO, Chester Billingsley. Edward Mashek, the CEO of Brighter Day Health, explains, “Telemedicine is the fastest growing method of delivering face-to-face healthcare to patients in the United States. Brighter Day Health has been an early leader in this field and is partnering with Mentor Capital to finance our accelerated facility and video system additions.”
The Brighter Day Health portfolio addition brings Mentor Capital cancer and financial assets to $10 Million from $1.0 Million in November 2011. Mentor has approximately 2.9 Million basic shares outstanding and has traded in the quarterly range of $0.10 to $0.26 per share.
About Mentor Capital: Founded in 1985 by the current CEO, the company now targets its socially responsible acquisitions and investments exclusively toward leading-edge cancer companies. Mr. Billingsley began his cancer involvement in graduate school at MIT where he studied difficult to treat cancers in conjunction with Mass General Hospital. He took Mentor Capital public in 1994, secured approval of the current $125 Million public funding structure and is the 2009 author of the Cancer Immunotherapy Index. Mentor works to find the best of non-profit cancer discoveries and finance their development toward a planned exit by sale to a large Pharma or by assisting the cancer fighting company to separately go public. Additional important information is presented at: www.MentorCapital.com